http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5108359-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49d6cbc1dd7c9ccbd4d635fc40b48ec5
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-40
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N2-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-40
filingDate 1990-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1992-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02d1054902d9f0e94a7a37542d4bd0ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b62cad92ad570e41c0eab190d0dc5cfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef0c4c3c36ce3b3e9072d5fa11ff76c3
publicationDate 1992-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-5108359-A
titleOfInvention Hemangioma treatment method
abstract The subject of this invention is in the field of medicine, particularly surgery, and is intended for the treatment of benign tumors and angiomas. A hemangioma is an angioma, or tumor, formed by an anomalous proliferation of vascular endothelium, forming an undesirable mass, which can occur anywhere in the body. The resulting disease is known as hemangiomatosis. The method of this invention is comprised of a reduction of the arterial blood flow to the hemangioma which limits the blood circulation in the tumor mass, thus creating favorable conditions for subsequent ferromagnetic embolization from externally and selectively applied electromagnetic or ultrasound energy and sclerotization of the tumor tissue, preventing the spread of ferromagnetic particles through the vessels and into other organs and systems. At the same time, maintaining the blood flow, though reduced, prevents the development of a total necrosis due to acute impairment of the tumor's blood circulation, which significantly reduces the general toxic effect. The reduced blood stream still leaves the possibility of introducing medication into the tumor, which reduces the possibility of complications during the postembolization period.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7083567-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003224056-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7007972-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7448389-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114948060-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2618457-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6436061-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7200956-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5618695-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6213933-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6993394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004122494-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6540657-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5498227-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5183456-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6544163-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7048756-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7670623-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6982501-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114948060-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7560160-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6850804-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5236410-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004105980-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9507732-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009081122-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5437600-A
priorityDate 1990-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4323056-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4622952-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4735796-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81070
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449449172
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9543089
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665772
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448908333
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129410028
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID373926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426145892
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226503711
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577472
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395837
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID159418
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23957
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5248
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395683
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP22775

Total number of triples: 66.